Phase 4 Glaucoma Trial, Recruiting NCT04957329 Sponsor: Rigshospitalet, Denmark Condition: Glaucoma
Back to Glaucoma

Phase 4 Glaucoma Trial, Recruiting

NCT04957329
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are over 18 years old
  • You speak Danish
  • You have been diagnosed with open angle glaucoma or high eye pressure (ocular hypertension)
  • Your average eye pressure reading is 22 mmHg or higher

Who may not be able to join:

  • You have a history of significant eye disease or eye injury, other than open angle glaucoma or high eye pressure
  • You have been treated with steroid medications within the last 3 months
  • You have a serious condition such as high blood pressure, heart failure, diabetes, stroke, lung disease, or an autoimmune disease that is not well controlled — note that these conditions are not a barrier if they are well managed or do not require treatment
  • You are currently pregnant or breastfeeding
  • You are a woman using a form of contraception considered unreliable or unsafe (confirm with trial site)
  • You have an allergy to the medication being tested in the trial
  • You are unable to cooperate with eye examination tests
  • You have damage or defects on the surface of your eye
  • You need more than one type of medication to treat your glaucoma

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Miriam Kolko, MD, PhD, Department of ophthalmology, rigshospitalet-Glostrup

Phone: +4522334504

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 September 2021
Est. completion
31 December 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Goblet cell density

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov